The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
32
Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
Sham injection
Asociacion para Evitar la Ceguera en Mexico
Mexico City, Mexico City, Mexico
RECRUITINGSafety and Tolerability of EO2002
Incidence of Treatment-Emergent Adverse Events
Time frame: 26 weeks
Endothelial Cell Density
Changes in ECD compared to baseline
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.